Generate to raise $425 million in ipo23 Feb 2026 21:03
Generate had a net loss of $223 million last year, higher than the net loss of $181 million it reported in 2024, according to its filing.
And here we sit debt free and with £15 mcap.
Solvonis Therapeutics (LON: SVNS) is not completely debt-free, but it has a very low debt level relative to its equity, often described as having a healthy balance sheet.
Simply Wall St
Simply Wall St
+1
Based on recent financial data (as of mid-to-late 2025):
Low Debt: The company has reported a total debt-to-equity ratio of approximately 1.1%.
Cash Position: Solvonis reported having more cash and cash equivalents than total debt.
Financial Health: The company has undergone significant restructuring and reduced its debt level from around 31.2% to 1.1% over the past few years